Vox Markets Logo

KR1, Prospex Oil & Gas, Xtract Resources and Vadim Alexandre on 2 healthtec stocks

12:27, 27th May 2020

Vox Media Player

DYOR Disclaimer

If you find this podcast useful please give it a rating and review on iTunes by clicking here

Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app


On today's Vox Markets Podcast: KR1, Prospex Oil & Gas, Xtract Resources and Vadim Alexandre on 2 healthtec stocks

George McDonaugh & Keld Van Schreven Co-Founders & Managing Directors of digital asset investment company #KR1 FOLLOW provide updates on some of their investments.

KR1 is a leading digital asset investment company supporting early-stage decentralised and open-source blockchain projects. Founded in 2016 and publicly traded in London (KR1:AQSE), KR1 has built a notable reputation for generating significant returns by investing in many key projects that are designed to power the decentralised platforms and protocols emerging to form new internet infrastructures.


Ed Dawson Managing Director of Prospex Oil & Gas #PXOG FOLLOW discusses some of the highlights from their 2019 final results and also discusses an outlook for 2020.

Prospex Oil & Gas plc is an AIM-quoted Oil & Gas investment company, which is building a sizable oil and gas investment portfolio, focusing on high impact, onshore and shallow, offshore European opportunities located in working hydrocarbon systems.

(Interview starts at 16 minutes 5 seconds)


Colin Bird, Executive Chairman of Xtract Resources #XTR FOLLOW outlines a general corporate update and further expresses why he's bullish on copper.

Xtract Resources plc is a diversified metals and minerals producer based in London, United Kingdom. The company's shares are traded on London Stock Exchange Alternative Investment Market. The primary focus of the company is gold and copper exploration and mining.

(Interview starts at 28 minutes 50 seconds)


Vadim Alexandre, Head of Healthcare at SP Angel discusses:

Feedback #FDBK FOLLOW

Cambridge Cognition #COG FOLLOW

Remdesivir

(Interview starts at 41 minutes 41 seconds)    

TwitterFacebookLinkedIn

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles
Watchlist